GLP-1 medications are not a permanent solution on their own - research on weight regain after discontinuation is ongoing, and many patients experience some weight regain after stopping therapy
24 Therefore, considering that GLP-1R is widely distributed in the body, that COPD and diabetes interact with each other and share common pathogenic mechanisms, and that GLP-1 and its receptor agonists have been widely used in diabetic patients and have demonstrated hypoglycemic, pro-inflammatory and anti-inflammatory factors, oxidative stress, neurogenesis and vascular protection, 33 then GLP-1 and its receptor agonists also have a role to play in COPD patients
During this window, your weight typically stabilizes if diet and exercise habits have been established
Emphasizing high-fiber content or gut-healthy bacteria can be effective, especially given common digestive issues among users
The future of BMI thresholds for GLP-1 access The BMI thresholds that define GLP-1 eligibility today are not permanent
It has several programs working and commanding at the same time